CytaCoat
CytaCoat and Absorbest announce development and licensing agreement for superabsorbent advanced wound care dressings
2024.09.06CytaCoat AB and Absorbest AB have entered into a development and licensing agreement to bring CytaCoat’s unique performance enhancing coating technologies to market in superabsorbent advanced wound dressings.
Read more
Segulah Medical Acceleration announces investment in Senzime
2023.09.28Segulah Medical Acceleraion AB (“SMA”) has made a commitment regarding an investment in Senzime AB (publ) (“Senzime” or “the Company”). As previously communicated in a press release from the Company, Senzime’s board of directors has resolved on a directed share issue of SEK 117 million, led by SMA together with Carnegie Fonder and existing shareholders Fjärde AP-fonden, Crafoordska Stiftelsen, Handelsbanken Fonder, Fredrik Rapp, and Swedbank Robur.
Read more
Collective Minds Radiology announces closing of SEK 84m financing, led by Segulah Medical Acceleration and existing shareholders
2023.08.28Collective Minds Radiology, a fast-growing, Swedish health-tech company with a mission to build the world’s largest platform and community for healthcare collaboration, announces the closing of a SEK 84 million funding round. The round was led by Segulah Medical Acceleration (“SMA”), a Scandinavia-based life science-focused investment company, together with existing shareholders, Brightly Ventures, Tradecity, Crista Galli Ventures, and several European business angels. The funding will enable Collective Minds to accelerate the commercial expansion of its professional healthcare collaboration platform for clinical consultation, education, and clinical research, with the aim of increasing the quality of care.
Read more
Navinci appoints Eva Pisa as chairman, further strengthens the leadership team and establishes a Scientific Advisory Board
2023.02.20In line with the company’s vision of becoming a leader in spatial proteomics, Navinci further strengthens its organization and is pleased to announce the appointment of Dr. Eva Pisa as new chairman of the board, Dr. Caroline Gallant as new CTO and the formation of a Scientific Advisory Board chaired by Professor Ulf Landegren.
Read more
Allurion to Go Public on NYSE
2023.02.16SMA portfolio company Allurion Technologies, a global leader in weight loss technology, to become publicly listed through business combination
Read more Segulah Medical Acceleration Announces Investment in Allurion Technologies
2022.09.13Segulah Medical Acceleration AB (“SMA”) has made a minority investment in US-based Allurion Technologies during their July 2021 extension of the $34m Series D financing. The Series D round was led by Novalis LifeSciences and Romulus Capital.
Read more Segulah Medical Acceleration Announces Investment in Navinci Diagnostics
2022.07.12Navinci Diagnostics AB, a Swedish life science company developing innovative tools for spatial proteomics research, announces the closing of SEK 90 million financing. The round was led by Segulah Medical Acceleration (”SMA”), a Scandinavia-based life science-focused investment company, together with existing shareholders, including Landegren Gene Technology AB, Nexttobe AB, and Beijer Ventures AB.
Read more
Signifier Medical Technologies is granted HCPCS Codes
2022.02.28Signifier Medical Technologies is granted HCPCS Codes for eXciteOSA to help patients access innovative technology
Read more Segulah Medical Acceleration Announces Investment in Signifier Medical Technologies
2021.07.30Segulah Medical Acceleration AB (SMA) announced today that it has invested in UK-based Signifier Medical Technologies’ USD 35 million Series D convertible financing. The financing was jointly led by SMA together with Angelus Venture Fund I L.P., Alan Howard (co-founder of Brevan Howard Asset Management) and Pioneer Healthcare Partners LP.
Read more
Segulah Medical Acceleration Announces Investment in SAGA Diagnostics
2021.06.30Segulah Medical Acceleration AB (SMA) announced today that it has invested in cancer liquid biopsy and genomic testing company SAGA Diagnostics’ oversubscribed SEK 106 million (€10.5 million) Series A2 equity financing round. The round was led by SMA together with the Sciety investment syndicate with strong support from existing shareholders such as Hadean Ventures.
Read more
Segulah Medical Acceleration Announces Investment in Quanta Dialysis Technologies
2021.06.28Segulah Medical Acceleration AB (SMA) a specialized growth equity investment firm focused on Medtech and related areas, announced today that it has invested in Quanta Dialysis Technologies oversubscribed and upsized $245 million Series D equity financing round. This financing is the largest ever private funding round for a dialysis device company.
Read more
Blue chip investors back new MedTech investment company
2021.04.29Segulah Medical Acceleration, SMA, is a newly formed company specializing in medical technology investments, with a focus on Sweden, Scandinavia and Western Europe. The company is financed by leading institutions and prominent private investors, whose initial commitments amount to approximately SEK 1.2 billion.
Read more